With our fully integrated LENS™ (Lead Evolution via Novel Synergies) Technology, you'll benefit from wide-ranging Fragment-based Lead Discovery (FBLD) expertise aimed at producing high-quality leads quickly.

• Libraries
• 800-compound collection chosen by structure-based drug discovery experts
• Synthetically accessible compounds
• Combination of readily accessible cores and novel Intellectual Property (IP)
• X-ray Crystallographic Screening
• Expertise with screening and structural determination of difficult drug targets
• Fully automated
• ACTOR™ crystal transfer/data collection
• MIExpert structure solution
• Complementary Screening
• Surface Plasmon Resonance
• Calorimetry
• Chemistry
• Parallel synthesis capabilities
• Rapid structure-guided lead optimization
• Early Lead through GMP manufacturing
• Pre-clinical development
• In vitro and in vivo assays
• Formulation and measurement of physicochemical properties